Researchers have isolated several genetic markers that could help identify individuals at risk for acute kidney injury (AKI) in the hospital setting (1). Results from the study presented at ASN Kidney Week 2014 in Philadelphia, PA, offer new clues about the pathogenesis of AKI. The findings could eventually lead to potential therapeutic interventions to help prevent kidney failure and premature death in thousands of patients who undergo cardiovascular surgery or other hospital interventions each year. Currently, AKI affects one in five hospitalized patients worldwide.

Collaborators from Yale University, Vanderbilt University, and the University of Western Ontario wanted to determine if they could identify patients who may have a higher genetic risk for developing AKI in the hospital. Doing so could uncover novel pathways that could be targeted for therapeutic interventions, said senior author Chirag R. Parikh, MD, PhD, FASN of Yale. Investigators in this multicenter study weren’t alone in their clinical suspicion that some individuals could have a genetic predisposition for developing AKI in the hospital setting. “What is clear is that patients of similar age and health status can have drastically different kidney outcomes after a potential insult like cardiopulmonary bypass surgery,” said Benjamin Humphreys, MD, PhD, FASN, of Brigham and Women’s Hospital and Director of the Harvard Stem Cell Institute Kidney Group in Boston. “Many patients do just fine, but others develop AKI. The absence of obvious clinical factors to explain these divergent outcomes suggests a role for genetic predisposition.”

Until recently, analysis methods limited the scope of genetic AKI studies. “The putative genetic components of AKI have until recent years been mainly investigated by hypothesis-driven research (of candidate genes),” Parikh said. “But technological progress in genotyping has opened the possibilities.”

Most Americans Aren’t Healthy Enough to Be Kidney Donors

Just over half of adults in the United States—including nearly two-thirds of African Americans—have health conditions that would preclude their becoming living kidney donors, according to a study presented at Kidney Week 2014. Anthony J. Bleyer, Jr., and colleagues of Wake Forest School of Medicine, Winston-Salem, NC, performed a population-based study to estimate the percentage of Americans healthy enough for kidney donation. The analysis included data on adults aged 21 to 70 years, drawn from The National Health and Nutrition Examination Survey 2010–2011. The investigators studied the presence of common factors that are used to exclude volunteers from donating a kidney in a representative sample of the United States population.

They found that 55.2 percent of the United States population would be ineligible to donate a kidney because of health conditions. A history of hypertension, the most common excluding condition, was present in 19.2 percent of participants. This was followed by obesity, 15.0 percent; excessive alcohol intake (more than four drinks per day), 11.6 percent; and diabetes, 11.5 percent.
HeRO (Hemodialysis Reliable OutFlow) Graft is the ONLY fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with **central venous stenosis**.

- **Fewer Infections**: 69% reduced infection rate compared with catheters¹
- **Superior Dialysis Adequacy**: 1.7 Kt/V, a 16% to 32% improvement compared with catheters¹
- **High Patency Rates**: Up to 87% cumulative patency at 2 years¹,²
- **Cost Savings**: A 23% average savings per year compared with catheters³

---

**Reducing Catheter Dependency**

**HeRO Graft Candidates**
- Catheter-dependent or approaching catheter-dependency
- Failing AVF or AVG due to central venous stenosis

**Treatment Algorithm**

1. Failing AVF or AVG due to central venous stenosis
2. AVF
3. AVG
4. HeRO Graft
5. Catheter

---

Learn more at [www.herograft.com](http://www.herograft.com)
Order at: **888.427.9654**

References:

Indications for Use: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. See Instructions for Use for full indication, contraindication and caution statements. Rx only.

HeRO Graft is classified by the FDA as a vascular graft prosthesis.

1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • Phone (888) 427-9654 • (770) 419-3355
All trademarks are owned by CryoLife, Inc. or its subsidiaries. HeRO Graft is a Hemosphere, Inc. product distributed by CryoLife, Inc. and Hemosphere, Inc. © 2012 CryoLife, Inc. All rights reserved.

---

1. Download the App
2. Scan the code with your mobile device to watch video

---

- HeRO Graft bypasses central venous stenosis
- HeRO Graft candidates
- Treatment algorithm
- Reducing catheter dependency
- References
- Indications for use
- HeRO Graft candidates
- Treatment algorithm
- Reducing catheter dependency
- References
- Indications for use
Kidney Donors

Continued from page 1

The rates of medical ineligibility were higher at lower levels of household income: 60.1 percent of individuals with an income below $35,000 would be unable to donate, versus 49.3 percent with an income above $100,000.

Financial pressures and immigration status are nonmedical factors that often affect the ability to be a kidney donor. With the addition of income below the poverty line and non–United States citizenship, 68.5 percent of the United States population would be ineligible to donate. The figure rose to 75.8 percent after the exclusion of smokers and of individuals with shortness of breath when walking up an incline.

There were significant racial and ethnic differences in the distribution of exclusionary medical conditions, with African Americans having the highest rates of obesity, hypertension, diabetes, and microalbuminuria. Overall, 63.9 percent of African Americans would be ineligible to donate, compared with 54.8 percent of whites.

There is a well-recognized shortage of living kidney donors in the United States. The new report is the first population-based study to evaluate the rates of specific medical conditions and social factors that would exclude individuals from living kidney donation.

“It is well known that African Americans and individuals with lower incomes are at an increased risk of kidney failure. Unfortunately, their potential donors—who are very likely to come from the same social groups—are also much less likely to be kidney donors due to comorbid conditions,” said Anthony Bleyer, the senior investigator in the study. “Increasing the number of living donors will require addressing this important issue.

“Increasing obesity and worsening health of the general population decrease the pool of potential donors. Financial compensation for time lost at work and lost income would likely improve the ability to donate in 36.1 percent of the eligible donor pool that has an adjusted family household income of less than $35,000,” Bleyer said.

Genetic Markers

Continued from page 1

Using GWAS methods, the investigators analyzed data from patients at risk for AKI in the hospital setting—760 adults with AKI and 669 adult controls who underwent surgery or received care in the intensive care unit (ICU)—to determine if any SNPs were associated with the development of AKI. The study population was selected from the surgical ICU (TRIBE-AKI study) and the medical ICU (VALID ICU cohort). AKI was defined as a rise in creatinine in the intensive care unit (ICU)—to determine if any SNPs were associated with the development of AKI. The study population was selected from the surgical ICU (TRIBE-AKI study) and the medical ICU (VALID ICU cohort). AKI was defined as a rise in creatinine of 0.55 to 0.72 mg/dL in 24 hours.

After genotyping a total of 992,895 SNPs, the researchers identified six clusters of six or more SNPs on six different chromosomes that are associated with a patient’s risk of developing AKI. Among these clusters, four (SOX2-OT, IL53, RAB20, and TAOK1) are intergenic (not coding information for protein synthesis) and the remaining 2 are intronic (coding information for protein synthesis). Using GWAS methods, the investigators analyzed data from patients at risk for AKI in the hospital setting—760 adults with AKI and 669 adult controls who underwent surgery or received care in the intensive care unit (ICU)—to determine if any SNPs were associated with the development of AKI. The study population was selected from the surgical ICU (TRIBE-AKI study) and the medical ICU (VALID ICU cohort). AKI was defined as a rise in creatinine of 0.55 to 0.72 mg/dL in 24 hours.

After genotyping a total of 992,895 SNPs, the researchers identified six clusters of six or more SNPs on six different chromosomes that are associated with a patient’s risk of developing AKI. Among these clusters, four (SOX2-OT, IL53, RAB20, and TAOK1) are intergenic (not coding information for protein synthesis) and the remaining 2 are intronic (coding information for protein synthesis).

Although it was a relatively small study, the results are promising, Humphreys said. “They clearly call for a much larger analysis to rigorously evaluate the association of these candidate SNPs with risk of AKI.” Parikh agreed, adding that “further collaborative research is required utilizing larger cohorts to confirm these findings and identify candidate genes that are mechanistically linked to pathogenesis of AKI.”

This study was supported by the National Institutes of Health R01HL085757 and P30 DK079310 O’Brien Kidney Center Grant.

Reference

Passing the Torch

Six years ago ASN Kidney News did not exist. The magazine came to life in January 2009. Over the years it has grown and developed, much like a child. Despite some early stumbles and falls, it has now learned to walk and talk and live.

As with my own children, ASN Kidney News has matured and readied itself to live without me. I know our new editor-in-chief, Richard Lafayette, MD, FACP, will help it mature further. However, I will miss my baby just the same. I have learned so much from this job, and it has provided me hours of joy (and some frustration) over the past six years.

This swan song would be incomplete without expressing my thanks to a number of people. First, the editorial advisory board provided inspiration and ideas for content and features. Next, I must thank those who wrote and edited articles and feature sections. I know many of you performed these tasks at least somewhat reluctantly, but your efforts made the magazine successful. I must thank the executive editor, Dawn McCoy. She will be continuing in her role, but I will miss our calls. I must also thank Kidney News designer Lisa Cain, who conceived the magazine’s original design and continues to work wonders with each monthly issue.

Finally, I want to encourage all members of the American Society of Nephrology to get involved in its efforts. The organization does a lot for us, but it needs the input and energy of its members to get it right. Volunteer for a group or committee. Sign up for political action alerts. And always read ASN Kidney News.

Pascale H. Lane, MD, FASN, is the outgoing editor-in-chief of ASN Kidney News. She will remain on the KN Editorial Advisory Board.
CORRECTION

The article, “20 Things to Know about Your ASN” in the October/November issue of Kidney News included incorrect numbers for ASN’s membership. Item 19 in the article should have read: “Of ASN’s 15,560 members, 5306 (34 percent) are from outside the United States.” The article incorrectly stated: “Of ASN’s 14,928 members, 5184 (41 percent) are from outside the United States.” The article, “20 Things to Know about Your ASN” in the October/November issue of Kidney News included incorrect numbers for ASN’s membership. Item 19 in the article should have read: “Of ASN’s 15,560 members, 5306 (34 percent) are from outside the United States.” The article incorrectly stated: “Of ASN’s 14,928 members, 5184 (41 percent) are from outside the United States.” Kidney News apologizes for the error. The numbers are stated correctly in the online KN.
RRT Can Play a Critical Role in Treating Ebola Patients

By Eric Seaborg

Recent Ebola cases have shown that dialysis can play a key role in the survival of critically ill patients. Given the potential importance of renal replacement therapy—especially fluid replacement—in patients with Ebola virus disease (EVD), nephrologists need the time needed for a patient’s body to mount an immune response to overcome the viral attack, at least in some cases. Ebola has several effects that can lead to acute kidney injury (AKI) and the need for RRT. These effects include massive fluid loss from vomiting and diarrhea leading to hypovolemia, a systemic inflammatory response syndrome, hemorraghing, and clotting abnormalities that increase susceptibility to bleeding, and more, said Sarah Faubel, MD, professor of medicine at the University of Colorado, Denver, and head of ASN’s AKI Advisory Group. Faubel also spoke at the Kidney Week special session “The medical indications for renal replacement therapy in Ebola virus are similar to those in other patients with acute kidney injury; and involve considerations such as volume control, electrolyte balance, and the severity of kidney dysfunction,” Faubel said. “In critically ill patients, nephrologists have great experience in considering the risks and benefits of RRT, and the medical decision to start it should follow the usual course.” The decision may be different, Faubel said, but the implementation is different because of the need to isolate the patient. A unique aspect of Ebola treatment is that staff protection is as important as the patient outcome. “You will not succeed unless you have an isolation environment that protects your staff safety and the safety of the community,” Faubel said. “The biggest lesson in terms of treatment of Ebola patients is that you have to play by the rules of the isolation unit,” Faubel told Kidney News. “When you are in an operating room, you have to do everything according to operating room standards to protect the patient. When you are in an isolation room, you have to do everything according to isolation procedures to protect the staff from infection.” A hospital should develop its plan for dealing with an Ebola patient well before any patient arrives. These plans should follow Centers for Disease Control and Prevention (CDC) guidelines and local community health department recommendations, Faubel said. “Given the potential need for dialysis and the complexity of performing dialysis in patients with Ebola virus disease (EVD), nephrologist involvement is essential in the planning phases of hospitals intending to care for patients with EVD,” a guidance document developed by ASN recommends. The plan should address questions such as the use of anticoagulation, an approach for laboratory testing, and how to handle dialysis effluent and the other medical wastes. (Many of these treatment resources can be found online—see sidebar.) For effective planning, nephrologists need a realistic idea of the infectivity of the virus. Ebola virus is spread through direct contact with blood from infected patients, but can also spread via contact with other fluids such as urine, sweat, vomit, and diarrhea.

Faukel said that Ebola is more like hepatitis B than HIV: “It can survive on surfaces about as long as hepatitis B, which isn’t that long, but is long enough. It is not like HIV, which dies pretty much as soon as it gets on a surface. Ebola is a lipid-coated virus, so once you really dry it out, it dies. In a dialysis unit, you have to isolate hepatitis B patients, but you don’t have to isolate HIV patients.”

One factor that makes Ebola so infectious is its very high levels—in the billions of viruses per milliliter of blood—and it can also be present on the patient’s skin. It is not transmitted through the respiratory route like influenza, but aerosolized bodily fluids are infectious. These characteristics call for extra caution in dialysis set-up, and argue for the use of continuous RRT to minimize blood spill possibilities.

The case of Thomas Eric Duncan in Dallas, in which two nurses treating him became infected, led the CDC to tighten its guidelines to recommend that personal protective equipment have full body coverage for all workers caring for Ebola patients.

The Emory team adopted procedures designed to minimize the possibility of healthcare worker exposure. “We dedicated a pressure-controlled room, used point-of-care laboratory testing, [and used] dedicated ultrasound and x-ray machines that never left the room. Blood cultures were performed in the room and consulting physicians did not enter the room unless absolutely required,” Faubel said. Much of the care relied on ICU nurses with specialized training in isolation protocols and in continuous RRT who volunteered for the duty, but some on-the-spot training was unavoidable.

They followed isolation procedures such as checking the integrity of the protective gear of those entering and exiting the isolation unit. The team used a single dialysis machine “with a small footprint that could stay in the room and had the flexibility to perform both continuous and intermittent modes of dialysis,” Faubel said, and anything that went into the isolation unit stayed there. In keeping with Kidney Disease Improving Global Outcomes AKI guidelines, the team put the cannula in the right internal jugular, which is its local practice. Line placement is considered a center-specific consideration, and hospitals should stick with practices they have experience with. This is no time to experiment with new procedures, Faubel said.

Faukel said that to minimize filter changes in the dialysis unit, the patient received anticoagulation therapy, which has its own problems because Ebola is a hemorrhagic disease. “For this reason, we used regional citrate anticoagulation with peripheral calcium replacement and regular ionized calcium measurements. While this approach worked extremely well, alkalosis from metabolism of the citrate does become a problem,” Faubel said.

Emory University Hospital successfully treated a pair of other patients whose kidney function remained normal despite arriving from Africa on day 10 and day 14 of their illness. The RRT patient was admitted much earlier, on day 4 of his disease, and developed AKI despite the aggressive supportive therapy. Some observers have doubted whether continued treatment could work when the disease has progressed this far. But with RRT and other support, the patient’s immune system responded. “The biggest lesson is that someone can recover from this,” Faubel concluded.

Resources for Ebola Preparation and Treatment

As the Ebola epidemic reached beyond Africa with patients in the United States and Europe, ASN responded quickly with a wealth of resources, from a podcast on Ebola and dialysis to a well-attended special session at Kidney Week.

The Centers for Disease Control and Prevention and other healthcare leaders reacted as well, and ASN has gathered links to every topic related to nephrology at the page: http://www.asn-online.org/news/2014/1017-ebola.aspx

Some of the most important links on the page are:

- ASN Frequently Asked Questions Regarding Ebola Virus Disease and Dialysis
- CDC Recommendations for Safely Performing Acute Hemodialysis in Patients with Ebola Virus Disease in U.S. Hospitals
- A podcast featuring Harold Franch, MD, who successfully dialyzed a patient with Ebola, and Sarah Faubel, MD, chair of ASN’s Acute Kidney Injury Advisory Group, discussing Ebola’s effects on kidney function and considerations nephrologists should take into account when treating a patient with Ebola.

The page also includes links to a CDC fact sheet on personal protective equipment for Ebola, a CDC hospital checklist for Ebola preparedness, CDC Ebola resources, and the World Health Organization Ebola portal.

Emory University, where a patient was successfully treated using dialysis, has a webpage with “Emory Healthcare Ebola Preparedness Protocols”: http://www.emoryhealthcare.org/ebola-protocol/ebhc-message.html

Details on the treatment of this patient along with proposed clinical practice guidelines can be found in “Successful Delivery of RRT in Ebola Virus Disease,” published in Journal of the American Society of Nephrology: http://jasn.asnjournals.org/content/early/2014/11/13/ASN.2014111057.abstract

Another recent article about two other Emory patients, “Clinical Care of Two Patients with Ebola Virus Disease in the United States,” was published in the New England Journal of Medicine and can be found at: http://www.nejm.org/doi/full/10.1056/NEJMoa1409838
A total of 27 late-breaking clinical trials were presented at ASN Kidney Week 2014 in Philadelphia. These studies detailed new understandings and innovations in multiple therapeutic areas, including acute kidney injury (AKI), autosomal dominant polycystic kidney disease (ADPKD), dialysis, and diabetic nephropathy. This article highlights some of the leading science presented at the oral plenary High-Impact Clinical Trials session that potentially could influence the clinical approach of kidney health professionals in the United States and beyond.

HALT PKD trials

Two new prospective, multicenter randomized clinical trials sought to understand the influence of blood pressure control on disease progression and comorbidity burden in patients with ADPKD, the fourth leading cause of end stage renal disease (ESRD). A combination of two studies, the HALT PKD trials first evaluated the effects of rigorous blood pressure control on disease progression and whether combined antihypertensive therapies conferred an additional benefit.

The HALT A study enrolled 558 patients with early ADPKD to determine if rigorous blood pressure control conferred benefits over standard blood pressure control related to a reduced rate of increase in total kidney volume and greater declines in measures of heart and kidney problems (1). Healthy patients between 15 and 49 years old (with an eGFR greater than 60 mL/min/1.73 m²) were randomized to either standard blood pressure control (120–130/70–80 mm Hg) or low blood pressure control (95–110/60–75 mm Hg) groups. The primary end point was disease progression measured as percent change in total kidney volume.

Low blood pressure control was well tolerated and resulted in a 14.2 percent slower growth of total kidney volume over five years, while conferring benefits over standard blood pressure control related to a reduced rate of increase in total kidney volume and greater declines in measures of heart and kidney problems (1). Healthy patients between 15 and 49 years old (with an eGFR greater than 60 mL/min/1.73 m²) were randomized to either standard blood pressure control (120–130/70–80 mm Hg) or low blood pressure control (95–110/60–75 mm Hg) groups. The primary end point was disease progression measured as percent change in total kidney volume.

Glucose control could help reduce diabetic nephropathy incidence

Longitudinal data obtained in a post-trial observational study suggest that glucose control may be a key determinant for ESRD risk. The ADVANCE-ON Trial found patients who maintained strict glucose control demonstrated evidence of a sustained and significant reduction in ESRD over a long period of time with a median of nearly 10 years.

Follow-up of 8,494 patients in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, which is the largest clinical trial on diabetes, revealed that intensive glucose control leads to long-term reductions in the risk of developing ESRD (3).

“Our study also suggests that the benefits are greatest when treatment is begun early in the course of the disease, and in people in whom blood pressure is well-controlled,” said lead author Vladko Perkovic, MBBS, PhD, FASN. “These results suggest that finding better ways to control glucose levels is key to preventing the epidemic of kidney failure due to type 2 diabetes around the world.”

New understandings in AKI

Two studies evaluated potential therapies for AKI in the hospital setting, a common complication that can lead to kidney failure and in some cases death.

The first examined the use of aspirin and clonidine with non-cardiac surgery to determine if it could reduce the incidence of AKI. “We need treatments to prevent AKI in the surgical setting, and early data suggested taking aspirin in this regard might be beneficial,” said Amit Garg, MD, the study’s author. The substudy of the PeriOperative iSHcemic Evaluation-2 (POISE-2) Trial included 695 patients undergoing non-cardiac surgery. Investigators found that use of aspirin around the time of surgery increased the risk of major bleeding, which was associated with a greater risk of subsequent AKI. The use of clonidine (a medication used to treat hypertension) around the time of surgery increased the risk of low blood pressure, which was associated with a greater risk of subsequent AKI.

Compared with placebo, neither aspirin nor clonidine altered the risk of most AKI observed after major non-cardiac surgery. “Approximately 200 million adults undergo major non-cardiac surgery each year, and among patients taking aspirin prior to surgery there is substantial practice variability as to whether it is held or not in the perioperative period,” the study investigators noted (4).

Another AKI study evaluated the use of mesenchymal stem cells in patients undergoing cardiac bypass surgery. The ACT-AKI study built on previous work that demonstrated the cells’ potential to prevent AKI and promote recovery of renal function after it occurred. A trial of 156 patients who developed AKI following cardiac surgery found that treatment with certain stem cells did not shorten the time it took patients to achieve complete kidney recovery, nor did it decrease their risk of dying prematurely or needing dialysis. Unfortunately, “AKI is a common condition and there is no effective treatment,” the researchers said (5).

Advances in dialysis reported

Several studies reported research on innovations in care for patients on dialysis. The first study examined a new approach to in-stance reteniosis, a common problem in this population. It included 265 dialysis patients, and found that the Fluency® Plus Endovascular Stent Graft—which is placed inside a blocked stent to re-open it and allow adequate blood to flow and dialysis to take place—was superior to balloon angioplasty alone through 6 months. The Fluency® Plus Endovascular Stent Graft was better for restoring blood flow and keeping the area open longer. “In-stance reteniosis is a common problem in the care of ESRD patients. This study represents the first level-1 evidence for the use of stents-grafts in the treatment of both arteriovenous fistula and arteriovenous graft stenosis,” said lead author Alexander Yezewski, MD (6).

Another, ACTIVE Dialysis Multinational Trial, examined the use of extended hemodialysis hours to determine if it would improve patient outcomes. Among 200 patients on dialysis, extending weekly dialysis hours for 12 months did not improve quality of life, but was linked with improvements in some laboratory measures (such as potassium and phosphate blood levels) and a reduced need for blood pressure medications (7).


References
At Amgen, we pour commitment, passion, and a drive for perfection into every biologic medicine we make.

From innovative biotechnology to extensive experience in biologic manufacturing, see how Amgen strives to deliver on its commitment to your patients.

For reliability and quality, our roots go deep

Take a deeper look at our reliability and quality
visit biotechnologybyamgen.com
Download the LAYAR app on your smartphone and scan this page.
Exercise May Slow Kidney Disease Progression

Patients with stage 3 to 4 chronic kidney disease (CKD) assigned to an exercise/rehabilitation intervention have better maintenance of kidney function at one-year follow-up, according to preliminary research presented at Kidney Week 2014.

In a pilot study, consultant renal physiotherapist Sharlene A. Greenwood of King’s College London and colleagues evaluated an exercise training program for patients with predialysis CKD. Ten patients received the study intervention, which consisted of thrice-weekly exercise sessions at a gym setting in a community hospital. Another 10 patients received usual care.

The exercise programs were individualized, accounting for patient choice and aiming for a combination of aerobic and resistance exercises. Aerobic exercise was predominantly performed on recumbent stationary exercise cycles, at an intensity corresponding to 80 percent heart rate reserve with maximum heart rate, based on incremental exercise testing. Resistance training was prescribed at 80 percent of one repetition maximum. The intervention also included an individual session with a senior renal physiotherapist for discussion of exercise and personal goals with use of a motivational interviewing approach.

Kidney function was assessed by comparing the rate of change in serum creatinine-based estimated GFR (eGFR) for each participant for 12 months before the study versus during the 12-month intervention period. Other outcomes of interest included pulse wave velocity, exercise capacity (VO2 peak), waist circumference, and body weight. Eight patients in the intervention group and 10 control individuals completed the study.

At the end of 12 months, patients assigned to the exercise/rehabilitation group had better preserved kidney function. The mean difference in eGFR was 7.8 mL/min/1.73 m2/year, compared with the usual care group.

Exercise/rehabilitation was also associated with reduced body weight and improved exercise capacity. After adjustment for baseline differences, patients in the intervention group had a 5.6 kg reduction in body weight and a 7.1 cm reduction in waist circumference, with a 5.7 mL/kg/min increase in relative VO2 peak.

There was also a significant 2.30 m2/second reduction in pulse wave velocity in the intervention group. The eGFR benefit was inversely correlated with the changes in pulse wave velocity and waist circumference.

Patients with stage 3 to 4 CKD have reduced exercise capacity, which may contribute to their risk of cardiovascular disease—the leading cause of death in CKD. Exercise training has the potential to preserve kidney function and improve cardiovascular risk factors in predialysis patients with CKD.

This pilot study suggests substantial benefits of an exercise/rehabilitation program for patients with stage 3 to 4 CKD. The benefits include a slower decline in kidney function after 12 months of exercise training, compared with usual care.

Together with improvements in exercise capacity and body weight, the exercise/rehabilitation program may be associated with improved quality of life in this group of patients. Although small, our study suggests that long-term tailored exercise prescription with motivational interviewing is a feasible approach for exercising patients with progressive CKD, and sets the scene for a large multicenter study,” Greenwood said.

New Findings on Diet and Kidney Disease

Research presented at Kidney Week 2014 highlights dietary factors affecting kidney disease outcomes—including a study reporting that a “healthy diet” and lower sodium intake are associated with a reduced risk of major renal outcomes. Another report draws attention to the potentially high levels of potassium added to some “reduced-sodium” foods.

Nephrologist Andrew Smyth, MB, of National University of Ireland Galway and his colleagues presented the results from the Diet and Health Study of the National Institutes of Health and the American Association of Retired Persons. On the basis of findings on food frequency questionnaires completed by nearly 545,000 participants, the researchers evaluated the relationship between diet quality, sodium and potassium intake, and major renal outcomes—dialysis or death from renal causes. The study evaluated several different definitions of a “healthy diet”: the Healthy Eating Index, the Alternate Healthy Eating Index, the Mediterranean Diet Score, and the Recommended Food Score, along with sodium and potassium intake.

On three of four diet quality measures, a healthy diet was associated with a lower risk of dialysis or death from a renal cause; there was no association with the Recommended Food Score, along with sodium and potassium intake. On three of four diet quality measures, a healthy diet was associated with a lower risk of dialysis or death from a renal cause; there was no association with the Recommended Food Score, along with sodium and potassium intake. On three of four diet quality measures, a healthy diet was associated with a lower risk of dialysis or death from a renal cause; there was no association with the Recommended Food Score, along with sodium and potassium intake.

The risk was 19 percent higher for participants in the highest quintile of sodium/potassium ratio. The researchers conclude, “Our findings extend the known benefits of healthy eating and show that the consumption of a healthy diet, including reducing sodium intake from high levels and increasing potassium intake, may protect from future major renal endpoints.” Anti Sharma Pappas, RD, of St. Michael’s Hospital, Toronto, and colleagues from the University of Toronto evaluated the protein, sodium, phosphorus, and potassium content of “reduced-sodium” meat and poultry products sold at grocery stores. “Food manufacturers may use phosphate and potassium additives to replace the functional and flavor properties of sodium, and the amount is usually not listed on food labels,” the researchers wrote.

They found that sodium-reduced products contained 25 to 55 percent less sodium than their non–sodium-reduced counterparts: the mean difference was 460 mg per 100 g. The sodium-reduced products also contained on average 47 percent more potassium, with a wide variability in potassium content: from 210 to 1500 mg per 100 g. Potassium-containing additives were found on the ingredients list of 63 percent of sodium-reduced products, compared with 25 percent of non–sodium-reduced products. Phosphorus and protein levels did not differ for the two groups of products. “Potassium additives are frequently added to sodium-reduced meat and poultry products in amounts that significantly contribute to the potassium load for CKD patients,” the researchers conclude. “Patients requiring a potassium restriction should limit their intake of sodium-reduced meat and poultry products.”
Poor Air Quality Linked to CKD Risk

Could differences in air quality contribute to the observed regional variations in chronic kidney disease (CKD)? A study presented at Kidney Week 2014 finds a higher prevalence of recognized CKD in counties of the United States with higher particulate air pollution.

Epidemiologist Jennifer L. Bragg-Gresham, PhD, of the University of Michigan and colleagues evaluated differences in pollutant levels—specifically, fine particles smaller than 2.5 μm (PM$_{2.5}$)—as potentially contributing to regional differences in CKD prevalence.

On the basis of Medicare claims data from 1.1 million persons aged 65 years and older, the prevalence of CKD by county ranged from zero to 60 percent, with a median of 16 percent. Associations between levels of PM$_{2.5}$, determined from U.S. Environmental Protection Agency air-quality data made publicly available through the WONDER online database of the Centers for Disease Control and Prevention, and prevalence of recognized CKD in the Medicare data were analyzed.

“We found that poorer air quality was associated with a higher prevalence of CKD,” Bragg-Gresham and coauthors write. With PM$_{2.5}$ treated as a continuous variable, each increment of 4 μg/m$^3$ in PM$_{2.5}$ was associated with a 3 percent higher CKD prevalence, after adjustment for individual-level confounders.

When counties were grouped by quartiles of PM$_{2.5}$, a threshold at approximately 14 μg/m$^3$ was observed for higher CKD prevalence. This is much lower than the level typically considered unhealthy (40 μg/m$^3$) for sensitive groups, such as children, the elderly, and people with cardiorespiratory disease.

Well-recognized individual risk factors, such as age, diabetes, and hypertension explain some, but not all, of the wide regional variation in CKD prevalence. As yet unrecognized environmental factors, such as air pollution, might account for some part of the additional variability.

Although observational studies cannot show causal relationships, this large cross-sectional study suggests that higher PM$_{2.5}$ levels in a county are associated with higher rates of diagnosed CKD. The researchers call for further studies to clarify this relationship, including laboratory diagnosis of CKD, longitudinal designs, assessment of other air and environmental pollutants, and measures of individual pollutant exposure.

“If this association is borne out by future studies, it would have implications for reducing air pollution exposure for those with CKD and also for those at risk for the condition,” Bragg-Gresham said. “The potential public health significance of this finding is even greater for regions and countries with even higher levels of air pollution than the United States.”

---

Industry Spotlight

DaVita Activates Compliance after $400 Million Settlement

DaVita announced in May 2013 that it had set aside $300 million in case the company would be required to pay a federal fine, revealed CEO Kent Thiry, during what he termed a “sober” conference call to announce quarterly results. Eventually, the company had set aside a total of $414 million, so it would be prepared to pay for a potential violation of the False Claims Act when the time came.

The settlement money has finally come due, and amounted to $387 million plus interest accrued between February and October of this year.

In late October, the U.S. Department of Justice (DoJ) announced that DaVita had agreed to pay $350 million to resolve claims that the company had violated the False Claims Act. The claims included paying kickbacks to induce the referral of patients to DaVita dialysis clinics.

Headquartered in Denver, DaVita has dialysis clinics in 46 states and the District of Columbia. A fine of $39 million was also part of the settlement to the federal government, payment for forfeiture discovered in relation to the two joint ventures. (Forfeiture describes the process wherein a civil probe into two joint ventures involving DaVita and doctors. The $39 million civil forfeiture agreed to by DaVita was “based upon conduct related to two specific joint venture transactions entered into in Denver,” the office said, implying that ownership although crimes were not discovered in relation to the two joint ventures. (Forfeiture describes the process wherein a civil court, after all the interested parties have had a chance to make their case, orders a change in ownership of the property, without criminal charges.)

DaVita also will institute a strictly outlined compliance program through a Corporate Integrity Agreement that includes many required elements and potential fines if compliance requirements fail to be established, such as: “unwinding of the Subject Joint Venture Clinics, except to the extent covered by a Monitor’s certification.” The program calls for an independent monitor, a written code of conduct, detailed training of DaVita staff and others covered under the settlement, including board members; and hiring a chief compliance officer.

Now DaVita will have to start entering into transactions that uncouple 11 of the same clinics it worked to partner with. The settlement noted that for 9 years, until February 2014, DaVita had identified physicians or physician groups with patient populations suffering from renal disease. DaVita, the claim said, “offered them (the physicians) lucrative opportunities to partner with DaVita by acquiring or selling an interest in the dialysis clinics to which their patients would be referred,” and the physicians also could not compete with the DaVita clinics nor refer patients to other dialysis providers.
Policy Update

CMS Final Rule for 2015 Holds No Surprises
By Mark Lukaszewski

On Friday, October 31, 2014, the Centers for Medicare & Medicaid Services (CMS) released its 2015 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Incentive Program (QIP) final rule for calendar years 2017 and 2018. This article provides a basic overview of the key takeaways of the rule.

After close inspection, ASN has concluded that the final rule did not contain any unexpected adjustments to the ESRD PPS or QIP and does not differ substantially from the proposed rule. The society determined it is likely that the 2015 rulemaking cycle will have a more pronounced effect on the program, as CMS is expected to provide further clarity on how new drugs may be added to the bundle, as well as make changes to the low-volume adjuster.

ESRD PPS
CMS finalized every aspect of the Protecting Access to Medicare Act (PAMA) pertaining to the ESRD PPS, including setting the base rate at a 0.1 percent increase from 2014 and delaying the inclusion of oral-only drugs until 2024. CMS noted that it believes the agency has the authority to add new services to the bundle, an issue that has recently been debated within the kidney community.

CMS addressed the provision of dialysis beyond the standard three times per week, restating its position that facilities must furnish medical justification for more frequent dialysis, and that dialysis modality choice does not constitute medical justification. The agency also stated that while it is not changing its policy regarding payment for drugs that are included in the PPS but are furnished for the treatment of ESRD, it recognizes that there is ongoing concern regarding patient access to prescription medications. CMS is considering various alternatives for dealing with this issue and plans to put our guidance in the near future.

Quality Improvement Program

In terms of the QIP, CMS finalized a proposal to implement a risk-standardized 30-day all-cause hospital readmissions (SSR) measure. ASN strongly supported this measure in concept but recommended against finalizing the measure owing to numerous concerns with the measure and methodology as designed. Notably, the National Quality Forum voted against the SSR measure when it was considered for endorsement this fall.

On a more positive note, CMS decided against adding a new measure to assess conditions treated by oral-only drugs, which is consistent with ASN’s encouragement to utilize a few highly meaningful measures rather than adding more watered-down measures. In addition, CMS finalized its proposal to remove the “High >12 g/dl anemia management measure,” a change ASN has supported for several years because the measure is topped out.

ASN, together with the greater kidney community, will continue to work together with CMS in order to make sure that the measures being developed guarantee the highest quality care possible for the millions of Americans with kidney disease. To learn more about this issue, or to read the ASN comment letter to CMS, please visit the ASN advocacy page at http://www.asn-online.org/policy/.

Final Physician Fee Rule Includes Wins for Kidney Community
By Mark Lukaszewski

On Halloween Eve 2014, CMS released the 2015 Physician Fee Schedule final rule, finalizing several important victories for ASN and other advocates in the kidney community.

A top ASN priority, also supported by other stakeholders, was to work with CMS to allow nephrologists to bill the full month of care when a home dialysis patient has been hospitalized during that month. CMS finalized the proposal it laid out in the proposed rule, which would allow nephrologists who complete monthly assessments of home dialysis patients and at least one face-to-face patient visit to bill for the full monthly Medicare code for home dialysis patients who are hospitalized that month. Previously, nephrologists had to bill the per diem code in months when their home dialysis patients were hospitalized. ASN and other advocates, including the Home Dialysis Alliance and Kidney Care Partners, supported this change.

Also in the final rule, CMS addressed concerns raised by ASN and others in the Continuing Medical Educa tional (CME) community that physicians attending certified CMS programs like ASN Kidney Week could get unfairly reported in the Open Payments program. The Open Payments program is an online federal initiative to increase transparency regarding physicians’ financial relationships with industry, such as gifts and travel. CMS established reporting rules that specifically exclude CME payments from the Open Payments program, including speaker-related payments and tuition support for attendees, so long as they are not directed by a commercial supporter.

Although CMS does not yet have the legal authority from Congress to designate patients’ homes as qualifying telehealth sites, ASN has and will continue to encourage both CMS and Congress to consider the potential benefits of adding the monthly capitation payment (MCP) services for home dialysis patients to the Medicare telehealth list as federal statute regarding telehealth sites evolves. This could enable more patients to consider dialysis at home, and reduce the travel burden for both patients and providers. CMS did note that it could pilot telehealth MCP care through its Innovation Center, opening up a new advocacy angle for 2015.

For more information on the final rule, please visit ASN’s policy webpage at http://www.asn-online.org/policy/.

Journal View

Dabigatran Linked to Excess Bleeding Risk

The risk of bleeding complications is increased for patients with arterial fibrillation taking dabigatran compared with warfarin—and patients with chronic kidney disease are among the highest-risk subgroups, according to a report in JAMA Internal Medicine.

The retrospective cohort study used pharmacy and medical claims data for a random 5 percent sample of Medicare beneficiaries in 2010 to 2011. Two groups of patients who started anticoagulant treatment within 60 days after diagnosis of arterial fibrillation were identified: 1302 receiving dabigatran and 8102 receiving warfarin. Episodes of major and minor bleeding by site were compared, with propensity score weighting to account for differences in patient characteristics.

Patients starting treatment with dabigatran had higher bleeding rates than did those starting warfarin: hazard ratio (HR) 1.30 for any bleeding event and 1.58 for major bleeding. The adjusted rates of major bleeding were 9.0 percent with dabigatran versus 5.9 percent with warfarin. The risk of gastrointestinal bleeding was also higher with dabigatran: HR 1.85.

The rates of most types of bleeding complications were higher with dabigatran, including hematuria (HR 1.41), vaginal bleeding (HR 2.27), hemorrhage (HR 2.78), and hemoptysis (HR 1.49). The exception was intracranial hemorrhage: HR 0.52 with dabigatran.

The excess bleeding risk remained significant in defined high-risk subgroups. The rates of major bleeding with dabigatran were particularly high for African American patients (HR 2.12) and for patients with chronic kidney disease (HR 2.07).

Soon after the approval of dabigatran, there were reports of severe bleeding events, particularly among elderly patients and those with renal impairment. Subsequent studies of this risk have yielded conflicting results.

This large analysis of Medicare beneficiaries with arterial fibrillation supports concerns about higher bleeding risk with dabigatran, compared with warfarin. The authors urge caution in prescribing dabigatran, especially to African Americans and patients with chronic kidney disease renal impairment. They also highlight the elevated risk of gastrointestinal bleeding across all patient subgroups.

The American Society of Nephrology thanks the following members for their dedication and service to the society concluding in 2014

Emaad M. Abdel-Rahman, MD, PhD, FASN
Christine K. Abrass, MD
Anupam Agarwal, MD, FASN
Charles E. Alpers, MD
Sharon P. Andreoli, MD
Mohammed Javeed Ansari, MD
Ralph C. Atkinson III, MD
James L. Bailey, MD
Carlton M. Bates, MD
L. Ebony Boulware, MD
Gregory Lee Braden, MD
Matthew D. Breyer, MD, FASN
Wendy Weinstock Brown, MD
Teri Browne, PhD
John M. Burkart, MD
Laura Byham-Gray, PhD
Thomas J. Carroll, PhD
Kerri L. Cavanaugh, MD
Kerry C. Cho, MD
Michel Chonchol, MD
Mark E. Cooper, MBBS, FASN
Dinna N. Cruz, MD
Stephen F. Darrow, MD
Ira D. Davis, MD
Tejas P. Desai, MD
Prasad Devarajan, MD
Zheng Dong, PhD, FASN
Jeremy S. Duffield, MD, PhD
Allison A. Eddy, MD, FASN
Fredric O. Finkelstein, MD
Michael F. Flessner, MD, PhD
Carlos D. Flombaum, MD
Joseph T. Flynn, MD, FASN
Agnes B. Fogo, MD
Susana L. Furth, MD
David Goldsmith, MD, FASN
Stuart Goldstein, MD
R. Ariel Gomez, MD
Debra J. Hain, PhD, APRN
Peter C. Harris, PhD
Catherine K. Hathaway, MD
Brenda Hemmelgarn, MD, PhD
Melanie P. Hoening, MD
Lawrence B. Holzman, MD
Thomas H. Hostetter, MD
Joanna Hudson, PharmD, FASN
Benjamin D. Humphreys, MD, PhD, FASN
T. Alp Ikizler, MD, FASN
Melanie S. Joy, PharmD, PhD, FASN
George A. Kaysen, MD, PhD, FASN
Donald E. Kohan, MD, PhD, FASN
Abhijit V. Kshirsagar, MD
Pascale H. Lane, MD, FASN
Kevin M. Lee, MD
Alan B. Leichtman, MD
Edgar V. Lerma, MD, FASN
Andrew S. Levey, MD
Moise Levi, MD, FASN
Christoph Licht, MD, FASN
Ruisheng Liu, MD, PhD
Xun-Rong Luo, MD, PhD
Glen S. Markowitz, MD
Teri J. Mauch, MD, FASN
Alicia A. McDonough, PhD
Bruce A. Molitoris, MD, FASN
Patrick H. Nachman, MD, FASN
N. Stanley Nahman, Jr., MD
Suzanne M. Norby, MD, FASN
Victoria F. Norwood, MD
Amy Barton Pai, PharmD, FASN
Dipen S. Parikh, MD
Samir M. Parikh, MD
Utpal D. Patel, MD
Martha Pavlakis, MD
Didier Portilla, MD
Caroline Jennette Poulton, MSW
Neil R. Powe, MD, FASN
Susan E. Quaggin, MD
Maria Pia Rastaldi, MD, PhD
Andrew J. Rees, MBChB
Rudolph A. Rodriguez, MD
Mark E. Rosenberg, MD, FASN
Mitchell H. Rosner, MD, FASN
Brad H. Rovin, MD, FASN
David J. Salant, MD
Jeff M. Sands, MD, FASN
Jeffrey R. Schelling, MD
Detlef O. Schlondorff, MD
Joseph I. Shapiro, MD, FASN
Andrey S. Shaw, MD
Michael J. Somers, MD
Stefan Somlo, MD
Matthew A. Sparks, MD, FASN
Titte R. Srinivas, MD
Wendy L. St. Peter, PharmD, FASN
Ana R. Stankovic, MD, FASN
Manikam Suthanthiran, MD, FASN
Timothy A. Sutton, MD, PhD, FASN
Jens Titzé, MD
Raymond R. Townsend, MD
Leonidas Tsikas, PhD
J. Kevin Tucker, MD
Delphine S. Tuot, MD
Robert J. Unwin, MD, PhD
Sushrut S. Waikar, MD
Karen M. Warburton, MD
Janet L. Welch, PhD
Paul A. Welling, MD
Roger C. Wiggins, MD
Alexander C. Wiseman, MD
Jack Work, MD
ASN Goes to NIH and PCORI

By Grant Olan

On September 19, 2014, ASN Secretary-Treasurer and Research Advocacy Committee Chair John R. Sedot, MD, FASN, joined other members of the committee and several of the society’s advisory groups to visit the National Institutes of Health (NIH) and Patient-Centered Outcomes Research Institute (PCORI) for “Kidney Research Advocacy Day.”

ASN began annual visits to NIH in 2012 to raise the profile of kidney disease, promote more kidney-related research, and encourage more cross-institute collaboration. This year, Kidney Research Advocacy Day participants met with leaders of the National Heart Lung and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and National Institute on Aging (NIA). The NIAMS and PCORI meetings were the first one-on-one meetings ASN has had with their leaders.

An internal ASN study of kidney research revealed that less than 1 percent of what the federal government spends on the cost of care for patients with kidney disease is invested in kidney research (approximately $80 billion in Medicare expenditures vs. $650 million for kidney research). The cost of just the Medicare End Stage Renal Disease (ESRD) program is nearly $35 billion, which is more than the entire budget for NIH (less than $30 billion in 2014).

Moreover, in 2013 NIH spent less per patient on kidney research vs. heart disease, cancer, and HIV/AIDS ($30 on kidney research per patient compared to $61, $534, and $2,898, respectively).

U.S. Congressional Kidney Caucus Co-Chair Rep. Tom Marino (R-PA) recently requested a review of federal investments in kidney research from the Government Accountability Office (GAO), a bipartisan agency that is highly regarded by Congress. Obtaining a congressional request for a GAO report on this topic is the cornerstone of ASN’s aggressive new Research Advocacy Strategic Plan to bolster support for more federal kidney research funding.

“I believe the GAO report is a crucial first step in understanding the current kidney research landscape, and anticipate it will confirm that kidney research is underfunded,” Dr. Sedot said.

“I believe the report will pay dividends for research funding down the line,” ASN President Jonathan Himmelstein, MD, FASN added. “Once complete, ASN looks forward to sharing the results with the entire kidney community.”

PCORI and each of the NIH institutes were receptive to ASN’s concerns and expressed interest in working with the society to advance kidney-related research. Below are some takeaways from the Kidney Research Advocacy Day meetings.

National Heart Lung and Blood Institute (NHLBI)
ASN met with Lawrence J. Fine, MD, Branch Chief, Clinical Applications and Prevention Branch, NHLBI, and other senior staff at the institute. NHLBI supports collaboration with NIDDK and kidney-related initiatives, such as an Ischemia-Chronic Kidney Disease ancillary study. Most heart trials exclude patients with advanced kidney disease despite the fact that heart disease is the leading cause of death for that population. ASN encouraged the institute to also measure albuminuria as well as collect and archive urine samples (for use by the research community) in the study and as many other studies as possible.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ASN met with NIAMS Deputy Director Robert H. Carter, MD, and other senior staff. NIAMS supports lupus nephritis research. A new NIH initiative called Accelerating Medicines Partnership (AMP) will explore possible biological pathways for treating lupus nephritis. AMP is a public-private partnership between NIH, industry, and nonprofit groups to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

National Institute of Biomedical Imaging and Bioengineering (NIBIB)
ASN met with NIBIB Acting Deputy Director William J. Heerdters, MD, PhD, and other senior staff. NIBIB supports an initiative called the Quantum Grants Program. The goal is to make a “grounding (quantum) impact on the prevention, diagnosis, or treatment of a major disease or national public health problem through the development and implementation of biomedical technologies within 10 years.” The program is funding a project to develop an implantable bioartificial kidney.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ASN met with NIDDK Director Griffin P. Rodgers, MD, Deputy Director Gregory G. Germino, MD, Kidney Urologic and Hematologic Diseases Division Director Robert A. Star, MD, and other senior staff. In addition to the issues outlined above, ASN and NIDDK discussed expanding NIH’s loan repayment to include adult bench research, a possible 2015 NIDDK health disparities initiative and other institute research funding priorities, and the Kidney Research National Dialogue.

National Institute on Aging (NIA)
ASN met with NIA Deputy Director Marie A. Bernard, MD, and other senior staff. NIA has supported kidney-related initiatives on acute kidney injury, organ donation, and renal function in older Americans. NIA has also supported initiatives to advance research on multiple chronic conditions such as the request for applications on “Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care.” ASN encouraged the institute to also consider initiatives in other areas where there has been little study, such as best management practices for older Americans nearing ESRD and kidney–mineral bone disorders.

Patient-Centered Outcomes Research Institute (PCORI)
ASN met with PCORI Chief Science Officer Bryan Luce, PhD, and other senior staff. PCORI is a new institute with a relatively small research grant portfolio and has provided more than $16 million in grants for kidney-related projects to date. PCORI recently announced a joint collaboration with NHLBI on a comparative effectiveness research initiative to study how to reduce disparities in treating hypertension. The initiative is only the second PCORI–NIH collaboration. The first was for a study on falls among the elderly with NIH.

ASN encouraged PCORI and NHLBI to consider kidney disease phenotypes given the significant association between the two.

Kidney Research Advocacy Day Participants
Frank C. Brosius, III, MD, University of Michigan Hospital
Josef Coresh, MD, PhD, FASN, Welch Center for Prevention, Epidemiology & Clinical Research
Deidra C. Crews, MD, FASN, Johns Hopkins University School of Medicine
William Fissell, MD, Vanderbilt University
Jordan A. Kreidberg, MD, PhD, Children’s Hospital Boston
Jeffrey H. Miner, PhD, Washington University Renal Division
John R. Sedot, MD, FASN, MetroHealth Medical Center
Mark L. Unruh, MD, University of New Mexico
Tushar J. Vachharajani, MD, FASN, W.G. (Bill) Hefner VA Medical Center
Efforts to Address Health Disparities: A Multipronged Approach

By Rachel Meyer

In many ways, kidney disease is the poster child for health disparities in the United States. In 2012, African Americans were nearly four times as likely and Native Americans nearly twice as likely as whites to experience kidney failure (1). African Americans, Hispanics, Native Americans, and Alaska Natives are twice as likely as whites to have diabetes, the leading cause of kidney disease. The incidence of ESRD in people with diabetes is six times as high in Native Americans compared with the incidence in the general population of diabetes patients. Moreover, minority populations spend more time on the wait list for a kidney transplant and are less likely to utilize a home dialysis modality (2).

Addressing these health disparities was a top ASN Public Policy priority in 2014, and in 2015 the society will continue to prioritize efforts at the federal legislative, regulatory, and profession-sanctioned levels to raise awareness and reduce disparities. Table 1 depicts ASN’s efforts to integrate health disparities advocacy into every aspect of the society’s 2014 policy priorities. ASN endeavors to ensure that Congress, federal research funding agencies, and Medicare are aware of these discrepancies and take every opportunity to confront them on behalf of the millions of Americans who are at disproportionate risk for kidney disease or compromised access to kidney care.

Table 1. 2014 ASN Policy Efforts to Address Health Disparities

<table>
<thead>
<tr>
<th>2014 ASN Public Policy Priorities</th>
<th>Efforts to Address Health Disparities</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Influence the evolution of the ESRD Quality Incentive Program and participate, in collaboration with the entire kidney community, in the bundle rebiasing process.</td>
<td>• Highlighted effects of proposed changes to the ESRD bundle and QIP on underrepresented minorities in all comment letters.</td>
</tr>
<tr>
<td>2. Shape the implementation and evaluation of the ESRD Seamless Care Organization (ESCO) program.</td>
<td>• Promoted the need for providers and practices of all sizes and types, serving all patient populations and geographic regions, to be able to participate in the ESCO program.</td>
</tr>
<tr>
<td>3. Develop and implement a long-range strategic plan regarding interactions with NIH and NIDDK, and continue to expand ASN’s research advocacy beyond NIH.</td>
<td>• Promoted health disparities research among and collaboration between federal research agencies and programs as ASN’s key research recommendation, including NIH and the VA’s research office, asked the GAO to specifically assess gaps in health disparities research as part of GAO’s assessment of the overall federal investment in kidney research funding.</td>
</tr>
<tr>
<td>4. Collaborate with other stakeholder coalitions to ensure a successful launch of the NIDDK Coalition.</td>
<td>• Advocated that the Friends of the NIDDK join ASN in emphasizing the importance of disparities research as a crucial, cross-cutting area in all interactions with NIDDK.</td>
</tr>
<tr>
<td>5. Promote recognition of Kidney Health Initiative (KHI) within FDA and Congress, and begin to develop policy positions on legislation related to the FDA.</td>
<td>• Highlighted the fact that significant health disparities exist in kidney disease as an important reason to promote innovative technologies and therapies that could potentially help reduce inequities in risk, diagnosis, and care of underrepresented minorities.</td>
</tr>
<tr>
<td>6. Foster the interest of younger and more diverse nephrologists in public policy issues, including establishing a policy track at Kidney Week.</td>
<td>• Ensure diversity in terms of speaker and moderator selection in public policy sessions.</td>
</tr>
<tr>
<td>7. Identify potential legislative or regulatory strategies to address the declining interest in nephrology careers.</td>
<td>• Explored developing federal loan repayment programs that support underrepresented minorities in all comment letters.</td>
</tr>
</tbody>
</table>

1. USRDS, 2014.
ASN Highlights US
Translating Kidney Week into Clinical Practice

ASN Highlights is a clinically focused educational opportunity, translating Kidney Week 2014 into practical advice with clinical relevance. The new ASN Highlights format is designed to help you incorporate the best of Kidney Week into patient care.

Why Attend?
- 7.5 CME credits
- Meet-the-Expert Roundtables
- Panel Discussions & Debates
- Networking with local colleagues

Topics Include:
- AKI
- ESRD
- General Nephrology & CKD
- Glomerular Diseases
- Hypertension
- Transplantation

Three locations; same great content:
- **Chicago, IL**
  - Friday, February 13 (full day)
- **Houston, TX**
  - Friday, February 20 (full day)
- **Orlando, FL**
  - Friday, February 27 & Saturday, February 28 (half days)

Contact:
rhonda.truitt@wt-group.com
P: 443-512-8899 x. 106 F: 443-512-8909

www.asn-online.org/highlights
In a subgroup of patients with hyponatremia (N = 475, serum sodium <135 mEq/L) enrolled in a double-blind, placebo-controlled trial, 18% (87/475) of patients treated with tolvaptan had serum sodium values >12 mEq/L/24 hours. In these studies, hyponatremia was a more frequent adverse reaction in patients treated with tolvaptan (11%) compared to placebo (2%). In addition, the median duration of treatment was 9 months. In these trials, the most common adverse reactions leading to discontinuation of therapy with tolvaptan in patients with hyponatremia were thirst (16% [82/475]), nausea (12% [57/475]), and vomiting (12% [57/475]). The incidence of adverse reactions leading to discontinuation in patients treated with tolvaptan was similar to that observed in the placebo group. In the placebo-controlled trials, the most common adverse reactions associated with placebo were nausea (19% [86/452]) and vomiting (17% [79/452]).

Toxicity of severe hyponatremia can cause serious neurologic sequelae (see BOXED WARNING). The most common adverse reactions leading to discontinuation of therapy with tolvaptan in patients with hyponatremia were thirst (16% [87/528]) and nausea (11% [59/528]).

In a subgroup of patients with hyponatremia (N = 475, serum sodium <135 mEq/L) enrolled in a double-blind, placebo-controlled trial, 18% (87/475) of patients treated with tolvaptan had serum sodium values >12 mEq/L/24 hours. In these studies, hyponatremia was a more frequent adverse reaction in patients treated with tolvaptan (11%) compared to placebo (2%). In addition, the median duration of treatment was 9 months. In these trials, the most common adverse reactions leading to discontinuation of therapy with tolvaptan in patients with hyponatremia were thirst (16% [82/475]), nausea (12% [57/475]), and vomiting (12% [57/475]). The incidence of adverse reactions leading to discontinuation in patients treated with tolvaptan was similar to that observed in the placebo group. In the placebo-controlled trials, the most common adverse reactions associated with placebo were nausea (19% [86/452]) and vomiting (17% [79/452]).

Liver Injury:

Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of hyponatremia. The risk of too-rapid correction of hyponatremia is greater if fluid restriction is inadequate or is withdrawn abruptly. In these trials, hyponatremia was a more frequent adverse reaction in patients treated with tolvaptan (11%) compared to placebo (2%). In addition, the median duration of treatment was 9 months. In these trials, the most common adverse reactions leading to discontinuation of therapy with tolvaptan in patients with hyponatremia were thirst (16% [82/475]), nausea (12% [57/475]), and vomiting (12% [57/475]). The incidence of adverse reactions leading to discontinuation in patients treated with tolvaptan was similar to that observed in the placebo group. In the placebo-controlled trials, the most common adverse reactions associated with placebo were nausea (19% [86/452]) and vomiting (17% [79/452]).

Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae (see BOXED WARNING):

Use in Patients with Renal Impairment:

Postmarketing Experience:

Mild to moderate impotence or priapism have been reported in men treated with tolvaptan. In patients with cirrhosis treated with tolvaptan in the hyponatremia trials, the incidence of impotence was similar to that of placebo (12% vs. 8%).

The impact of moderate CYP 3A inhibitors (e.g., erythromycin, fluconazole, aprepitant, diltiazem) on the exposure to co-administered tolvaptan has not been assessed. A substantial increase in the exposure to tolvaptan was observed in healthy subjects (see Dose and Administration (2.3) and Warnings and Precautions (4.5)).

There were no adequate and well controlled studies of SAMSCA use in pregnancy. Women should be advised to discontinue breastfeeding during therapy with SAMSCA.

DRUG INTERACTIONS:

There is no adequate and well controlled studies of SAMSCA use in pregnant women. In women who are breast-feeding, it is essential that adequate contraception be used during therapy with SAMSCA.

Osmotic demyelination syndrome has been reported in association with SAMSCA therapy. Therefore, the expected clinical effects of SAMSCA in the presence of multiple other risk factors (e.g., hypovolemia, hypotension, and hypoxia) should be considered when planning therapy.
For Clinically Significant Hypervolemic and Euvolemic Hyponatremia:
Serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction

INDICATION and Important Limitations
- SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
- Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA.
- It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

IMPORTANT SAFETY INFORMATION
SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadripareisis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.

Contraindications:
- Urgent need to raise serum sodium acutely, inability of the patient to sense or appropriately respond to thirst, hypovolemic hyponatremia, concomitant use of strong CYP 3A inhibitors, anuric patients, and hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components.

Warnings and Precautions:
- Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium or develop neurologic sequelae, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction should generally be avoided during the first 24 hours.
- SAMSCA can cause serious and potentially fatal liver injury. Avoid use in patients with underlying liver disease, including cirrhosis, because the ability to recover may be impaired. Limit duration of therapy with SAMSCA to 30 days.
- Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted. In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended.
- Co-administration with hypertonic saline is not recommended.
- Avoid concomitant use with: CYP 3A inhibitors and CYP 3A inducers. The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors.
- Monitor serum potassium levels in patients with a serum potassium >5 mEq/L and in patients receiving drugs known to increase serum potassium levels.

Adverse Reactions:
- The most common adverse reactions (SAMSCA incidence >5% more than placebo, respectively): thirst (16% vs 5%), dry mouth (13% vs 4%), constipation (7% vs 2%), pollakiuria or polyuria (11% vs 3%) and hyperglycemia (6% vs 1%).

Gastrointestinal Bleeding in Patients with Cirrhosis:
- In patients with cirrhosis in the hyponatremia trials, GI bleeding was reported in 10% of tolvaptan-treated patients vs 2% for placebo.

Please see Brief Summary of FULL PRESCRIBING INFORMATION, including Boxed WARNING, on following page.